Published in
American Association for the Advancement of Science, Science Translational Medicine, 565(12), 2020
DOI: 10.1126/scitranslmed.abb0391
Links
Tools
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors
Journal article published in 2020 by
Iván Márquez-Rodas 
,
Federico Longo ,
Maria E. Rodriguez-Ruiz ,
Antonio Calles ,
Santiago Ponce ,
Maria Jove,
Belén Rubio-Viqueira ,
Jose Luis Perez-Gracia,
Rosa Álvarez ,
Rodriguez Ruiz Me,
Ana Gómez-Rueda ,
Ainara Soria-Rivas,
Sara López-Tarruella ,
Mariano Ponz-Sarvise ,
Enrique de Miguel
and other authors.
,
Federico Longo ,
Maria E. Rodriguez-Ruiz ,
Antonio Calles ,
Santiago Ponce ,
Maria Jove,
Belén Rubio-Viqueira ,
Jose Luis Perez-Gracia,
Rosa Álvarez ,
Rodriguez Ruiz Me,
Ana Gómez-Rueda ,
Ainara Soria-Rivas,
Sara López-Tarruella ,
Mariano Ponz-Sarvise ,
Enrique de Miguel
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Intratumoral BO-112 combined with systemic anti–PD-1 shows immunotherapeutic potential to control tumors in patients primarily refractory to anti–PD-1.